Ivy Shuman, MD
Emergency Medicine · Martinez, GANPI 1881693380
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 30.7% of the total. Reporting peaked in 2019 at $731 and has fallen 75.0% since, to $182 in 2023. Among emergency medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$814
- Neurocrine Biosciences, Inc.$374
- Teva Pharmaceuticals USA, Inc.$260
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$253
- Johnson & Johnson$230
- Vanda Pharmaceuticals Inc.$202
- plus $523 from 5 others
What the payments were for
- Food & beverage$2,60898%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $814 |
| Neurocrine Biosciences, Inc. | 30 | $374 |
| Teva Pharmaceuticals USA, Inc. | 10 | $260 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $253 |
| Johnson & Johnson | 15 | $230 |
| Vanda Pharmaceuticals Inc. | 8 | $202 |
| Otsuka America Pharmaceutical, Inc. | 11 | $196 |
| Alkermes, Inc. | 11 | $190 |
| Sunovion Pharmaceuticals Inc. | 8 | $104 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$125
How this compares
$2,655 in reported general payments places this provider in the 95th percentile of 1,299 emergency medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 18 | $146,562 |
| VraylarCariprazine Hcl | 51 | $76,554 |
| RexultiBrexpiprazole | 26 | $43,243 |
| Invega SustennaPaliperidone Palmitate | 11 | $38,807 |
| CaplytaLumateperone Tosylate | 11 | $18,506 |
| Risperidone ErRisperidone Microspheres | 12 | $11,558 |
| Aripiprazole | 77 | $6,992 |
| Olanzapine | 135 | $3,661 |
| Quetiapine Fumarate | 187 | $3,432 |
| Haloperidol Decanoate | 26 | $2,809 |
| Risperidone | 153 | $2,487 |
| Bupropion XlBupropion Hcl | 51 | $1,923 |
| Haloperidol | 43 | $1,889 |
| Buspirone Hcl | 121 | $1,786 |
| Oxcarbazepine | 11 | $1,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $374 | $146,56218 claims |
| AbbVieVraylar | $814 | $76,55451 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $196 | $43,24326 claims |
| Johnson & JohnsonInvega Sustenna | $230 | $38,80711 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $253 | $18,50611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,299 emergency medicine providers in Georgia.
Other emergency medicine in Martinez
- Stephen MartinMarietta$1.8M
- Charles PollackRoswell$378K
- Michael BlaivasAugusta$284K
- Felicia PharagoodDuluth$144K
- Anna YaffeeAtlanta$101K
- Frank RaslerLilburn$58K
- Nicole HaigEast Point$57K
- Amy HubertCanton$40K
- Sean SueAtlanta$28K
- Emma SizemoreAtlanta$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.